Fiduciary Trust Co Has $4 Million Stock Holdings in CVS Health Co. (NYSE:CVS)

Fiduciary Trust Co decreased its stake in shares of CVS Health Co. (NYSE:CVS) by 17.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 89,134 shares of the pharmacy operator’s stock after selling 19,017 shares during the quarter. Fiduciary Trust Co’s holdings in CVS Health were worth $4,001,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Whitebox Advisors LLC acquired a new stake in CVS Health in the fourth quarter valued at $249,000. Principal Financial Group Inc. lifted its stake in CVS Health by 4.8% in the 3rd quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator’s stock valued at $90,200,000 after purchasing an additional 66,244 shares during the last quarter. Hall Laurie J Trustee grew its holdings in CVS Health by 25,484.4% during the fourth quarter. Hall Laurie J Trustee now owns 11,513 shares of the pharmacy operator’s stock worth $517,000 after purchasing an additional 11,468 shares during the period. B&D White Capital Company LLC acquired a new position in CVS Health during the fourth quarter worth approximately $417,000. Finally, Watts Gwilliam & Co. LLC lifted its position in shares of CVS Health by 9.8% in the fourth quarter. Watts Gwilliam & Co. LLC now owns 7,302 shares of the pharmacy operator’s stock valued at $334,000 after buying an additional 650 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on CVS shares. Edward Jones upgraded CVS Health from a “hold” rating to a “buy” rating in a research note on Thursday, January 30th. Wolfe Research raised their target price on shares of CVS Health from 67.00 to 70.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Leerink Partners upgraded shares of CVS Health from a “market perform” rating to an “outperform” rating and upped their price target for the company from $55.00 to $75.00 in a research note on Thursday, February 13th. Morgan Stanley restated an “overweight” rating on shares of CVS Health in a report on Tuesday, April 15th. Finally, Royal Bank of Canada increased their target price on CVS Health from $74.00 to $81.00 and gave the stock an “outperform” rating in a research note on Monday, May 5th. Three investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $74.81.

Insider Buying and Selling

In other news, SVP James David Clark sold 7,513 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the sale, the senior vice president now directly owns 8,394 shares in the company, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Michael F. Mahoney bought 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were acquired at an average price of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the transaction, the director now owns 39,356 shares in the company, valued at $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.22% of the stock is currently owned by corporate insiders.

CVS Health Trading Down 1.3 %

Shares of CVS opened at $66.98 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $72.51. The firm has a market cap of $84.45 billion, a price-to-earnings ratio of 18.30, a PEG ratio of 0.98 and a beta of 0.60. The business’s fifty day moving average is $66.96 and its 200-day moving average is $59.03.

CVS Health (NYSE:CVS) last issued its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, topping the consensus estimate of $1.62 by $0.63. The firm had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.31 earnings per share. Equities analysts anticipate that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.97%. The ex-dividend date was Tuesday, April 22nd. CVS Health’s dividend payout ratio (DPR) is 63.48%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.